Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Dyne Therapeutics, Inc.

NASDAQ: DYN · Life Sciences · 5 alerts · CIK 1818794

Share price
$16.70Close, Nov 16
Market cap
$3.13B
Shares outstanding
187.39MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Dyne Therapeutics, Inc. filings on SEC EDGAR ↗

4:09 PM ET Form 4
Insider Selling

Dyne Therapeutics CFO Erick Lucera Sells $33.5K of Stock

Erick Lucera, CFO, sold 1,991 shares of Dyne Therapeutics, Inc. at $16.82 a share, worth $33.5K in total on Nov 13, 2026. Shares held after the trade: 117,775 (-1.7%).

Value
$33.5K
Shares
1,991
Price
$16.82
Role
CFO
Holding change
-1.7%
Trade date
Nov 13, 2026
7:35 AM ET 8-K
Financial Results

Dyne Therapeutics Financial Results

Dyne Therapeutics reported Q3 2026 financial results, highlighting a cash position of $684.1 million to support operations into late 2026. The company is preparing for a potential Q1 2027 U.S. launch of z-rostudirsen for DMD, which is currently under FDA priority review with a PDUFA date of January 21, 2027.

Term
Q3 2026

“As we work toward potential commercialization, we are investing across multiple programs with the goal of unlocking the full value of our FORCE platform. This includes preparations for the potential U.S. launch of z-rostudirsen for exon 51 DMD, if approved, and topline data from the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, both expected in the first quarter of 2027.”

John Cox, president and chief executive officer of Dyne
7:26 AM ET 10-Q
Financial Results

Dyne Therapeutics Q3 2026 Results: Net Loss of $194M, Loss Widens

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on muscle diseases using its proprietary FORCE platform. As of October 30, 2026, the company had 187,386,963 shares of common stock outstanding and expects to require substantial additional funding to advance its product candidates, which are not anticipated to reach commercialization until at least 2027.

Key figure
Net loss $194M
4:15 PM ET Form 4
Insider Buying

Dyne Therapeutics Director Brian S. Posner Buys $40K of Stock

Brian S. Posner, Director, bought 2,500 shares of Dyne Therapeutics, Inc. at $16.00 a share, worth $40K in total on Oct 2, 2026. Shares held after the trade: 27,000 (+10.2%).

Value
$40K
Shares
2,500
Price
$16.00
Role
Director
Holding change
+10.2%
Trade date
Oct 2, 2026
4:11 PM ET 8-K
Clinical Trial Data

Dyne Therapeutics Clinical Trial Data

Dyne Therapeutics announced additional one-year clinical data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1), showing sustained functional improvement in myotonia, strength, and mobility. The data showed a 3.6-second relative improvement in hand myotonia at 6 months compared to placebo and divergence from a matched natural history cohort at 12 months. The company remains on track to report topline data from its registrational expansion cohort in Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in Q3 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.